This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
English to Spanish: Article from the Nature magazine General field: Science Detailed field: Medical: Pharmaceuticals
Source text - English Alzheimer’s drugs take a new tack
After a summer marred by disappointing clinical-trial results in patients with Alzheimer’s disease, drug developers are regrouping to plot a fresh course in the battle against the devastating disorder.
The bad news began in July and August, when Johnson & Johnson and Pzfier learned that their biological drug bapineuzumab had failed to show any benefit in two large trials. Then, on August 24, Eli Lilly said that its drug solanezumab had not hit its goal of slowing the memory decline and dementia that characterize Alzheimer’s disease.
Both of the failed drugs targeted amyloid-β, a protein that forms plaques in the brains of patients with the disease and that has long been the prime suspect for causing it. But rather than abandoning the amyloid hypothesis, scientists are pinning their hopes on innovative clinical-trial designs and new diagnostics that would allow them to test compounds earlier in the disease and gauge their efficacy more quickly.
Many worry, however, that investors spooked by the hundreds of millions of dollars spent on failed trials will be reluctant to support at continuing search for effective treatments for Alzheimer’s and other dementias, which affect and estimated 36 million people worldwide. “Money is tight”, says Husseini Manji, global therapeutic area head in neuroscience at Johnson & Johnson in New Brunswick, New Jersey. But “we are still committed. We think this is a major societal problem that needs tackling.”
Translation - Spanish Los medicamentos para el Alzheimner toman una nueva dirección
Tras un verano marcado por resultados de ensayos clínicos decepcionantes en pacientes con síndrome de Alzheimer, las empresas farmacéuticas se están reagrupando para idear un nuevo curso en la batalla contra el devastador desorden.
Las malas noticias comenzaron en julio y agosto, cuando Johnson & Johnson y Pzifier descubrieron que su fármaco biológico bapineuzumab no había logrado mostrar beneficio alguno en dos ensayos de envergadura. Posteriormente, el 24 de agosto, Eli Lilly anunció que su medicamento solanezumab no había alcanzado su objetivo de retardar el declive de la memoria y la demencia que caracterizan el síndrome de Alzheimer.
Ambos medicamentos fallidos estaban dirigidos a la β-amiloide, una proteína que forma placas en los cerebros de los pacientes con la enfermedad y que por largo tiempo ha sido la principal sospechosa de causarla. Pero en lugar de abandonar la hipótesis de la amiloide, los científicos están concentrando sus esfuerzos en innovadores diseños de ensayos clínicos y nuevos diagnósticos que les permitirían probar compuestos más temprano en la enfermedad y medir su eficacia más rápidamente.
Muchos se preocupan, sin embargo, de que los inversionistas, espantados por los cientos de millones de dólares gastados en los ensayos clínicos fallidos, se muestren reacios a apoyar la búsqueda continua de un tratamiento para el Alzheimer y otras demencias, las cuales afectan un estimado de 36 millones de personas alrededor del mundo. “El dinero escasea”, dice Husseini Manji, jefe global del área terapéutica en neurociencias de Johnson & Johnson en Nuevo Brunswick, Nueva Jersey. Pero “todavía estamos comprometidos. Creemos que este es un problema social grave que debe ser abordado.”
English to Spanish: Pharmaceutical study General field: Medical Detailed field: Medical: Pharmaceuticals
Source text - English Context: Nanotechnology is an empowering technology that holds promise in cancer therapeutics by increasing the ratio of tumor control probability to normal tissue complication probability. It can increase the bioavailability of the drug at the target site, reduce the frequency of administration and reach otherwise lesser-accessible sites. The present study shows the feasibility of the cisplatin-loaded albumin nanoparticle as a sustained delivery system.
Aims: Cisplatin is one of the most widely used chemotherapeutic agents for the treatment of malignant disorders. Conventional cisplatin formulation given as intravenous infusion has low bioavailability to the target organ in addition to significant side-effects, like ototoxicity and nephrotoxicity. The aim of this study was to develop a protein-based nanoparticulate system for sustained release of cisplatin.
Materials and Methods: Nanoparticles were prepared by the coacervaton method of microcapsulation and chemical cross-linking with glutaraldehyde. Particle size was characterized by dynamic light scattering and transmission electron microscopy.
Results and Conclusions: Using the coacervation method, nanoparticles of less than 70 nm diameter were produced. Drug encapsulation measured by ultraviolet spectroscopy varied from 30% to 80% for different ratios of cisplatin and protein. In vitro release kinetics shows that the nanoparticle-based formulation has biphasic release kinetics and is capable of sustained release compared with the free drug (80% release in 45 h). The study proves the feasibility of the albumin-based cisplatin nanoparticle formulation as a sustained release vehicle of cisplatin.
Translation - Spanish Contexto: La nanotecnología es una tecnología poderosa que tiene potencial en el tratamiento del cáncer al incrementar la proporción de la probabilidad de control del tumor contra la probabilidad de perjudicar el tejido normal. Puede incrementar la biodisponibilidad del medicamento en el lugar objetivo, reducir la frecuencia de administración y alcanzar sitios de otro modo menos accesibles. El presente estudio muestra la viabilidad de una nanopartícula albúmina cargada de cisplatino como sistema de liberación prolongada.
Objetivos: El cisplatino es uno de los agentes quimioterapéuticos más usados para el tratamiento de desórdenes malignos. La formulación convencional de cisplatino administrada como infusión intravenosa tiene una baja biodisponibilidad en el órgano objetivo, además de efectos secundarios significativos como ototoxicidad y nefrotoxicidad. El objetivo de este estudio era desarrollar un sistema de nanopartículas proteicas para la liberación prolongada de cisplatino.
Materiales y Métodos: Las nanopartículas fueron preparadas mediante el método de microencapsulación por coacervación y la reticulación con glutaraldehído. El tamaño de las partículas fue determinado mediante dispersión de luz dinámica y microscopio electrónico de transmisión.
Resultados y Conclusiones: Mediante el método de coacervado, se produjeron nanopartículas de menos de 70 nm de diámetro. La encapsulación del medicamento medida por espectroscopia ultravioleta varía de 30% a 80% para diferentes proporciones de cisplatino y proteína. La cinética de liberación in vitro muestra que la formulación nanoparticulada tiene una cinética de liberación de dos fases y es capaz de liberación prolongada comparada con el fármaco libre (80% de liberación en 45 h). El estudio prueba la viabilidad de la formulación de una nanopartícula albúmina como vehículo de liberación prolongada de cisplatino.
I am a translator and interpreter based in Fort Lauderdale, Florida. From a very early age, I showed great interest in video games and graphic novels. Fortunately (albeit it didn't seem so fortunate at the time), Latin American countries still had not caught much attention from the developed world, so the few titles that did get to the stores of my small hometown in Venezuela were only available in English. This is how I began developing my language skills: by banging my head against the screen every time I was unable to grasp the instructions for a quest in The Legend of Zelda: Ocarina of Time.
These episodes became less common with my discovery of the bilingual dictionary. Little by little, my abilities grew. At age 15, I became involved in the localization of video games and joined a team with the purpose of localizing the visual novel Fate/Stay Night. From there, I participated in the translation of other games, manga and comics.
I moved to the United States on 2009. I obtained an Associate of Arts degree in Biology from Broward College before furthering my education at Florida International University, where I am majoring in Asian Studies (Japanese) and minoring in Translation and Interpretation Studies.
Typical translation projects:
Video games
Graphic novels
Manga and light novels
Software
Websites
Scientific magazines
Due to my familiarity with medical terminology, I also accept medical interpretation assignments, such as Independent Medical Examinations (IME), from English into Spanish.
Summary of qualifications:
Native Spanish Speaker
Fluent Spanish Speaker
Advanced Japanese Speaker
Proficient user of: Word, Excel, PowerPoint, SDL Trados, MemSource, Adobe InDesign, Aegisub, and Sigil
Familiar with HTML and CSS
Detail-oriented
Ability to work under tight deadlines
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
